Motilal Oswal lifts Zydus Wellness target to Rs 600, sees 26% revenue CAGR through FY28
Post Q4, Motilal Oswal reiterates Buy on Zydus Wellness, citing core portfolio stability plus RiteBite and Comfort Click acquisitions. Brokerage models 26% consolidated revenue CAGR and 37% Ebitda CAGR over FY26-28E, valuing the stock at 23x FY27 and 18x FY28 EV/Ebitda.
Motilal Oswal reiterates Buy on Zydus Wellness with Rs 600 target post Q4, citing core stability and growth from RiteBite and Comfort Click acquisitions, modeling 26% consolidated revenue CAGR and 37% Ebitda CAGR over FY26-28.